Hydroxychloroquine-based COVID-19 Treatment, A Systematic Review of Clinical Evidence and Expert Opinion from Physicians’ Surveys

During the current COVID-19 epidemic, most of the evidence is collected by treating physicians, most of whom do not report their results in peer reviewed journals. Hence, there appears to be an especially broad gap between field experience and academic coverage of hydroxychloroquine-based COVID-19 treatments. The objective of this study is to bring field evidence into the academic literature.


Aussie Covid-19 Lockdown Chaos

Guest essay by Eric Worrall How not to run a Covid-19 lockdown; The Victorian Government has responded to a sudden winter surge in Covid-19 cases with a rushed hard lockdown, which has left vulnerable people living in government subsidised housing short of food. ‘It’s horrific’: Residents of Melbourne’s locked-down towers are struggling to receive essential…

Hypothesis: Restrictions on Hydroxychloroquine Contribute to the COVID-19 Cases Surge

Although Hydroxychloroquine remains an approved drug and doctors can still prescribe it off-label, the FDA’s and NIH’s opinions have significant influence. State governments and medical boards adhere to the FDA opinion, in their subsequent recommendations. Even when HCQ is not banned outright, such opinion creates a chilling effect on pharmacies, doctors, hospitals, and, especially insurance companies.